01 / PRODUCTION
Custom rAAV production
Produce AAV matched to your serotype, cassette, titer, and volume for your planned study.
AAV Product Resource
How to Choose the Right AAV Titer and Product Specifications for Your Experiment
AAV can be supplied at different titers, volumes, and aliquot formats, but higher titer is not always better. The right AAV specification is determined by the required total vector genomes, dosing volume, administration route, and quality profile—not by selecting the highest titer alone. Final selection should also consider genome integrity, full-to-empty capsid ratio, purity, functional activity, endotoxin, residual host-cell impurities, buffer composition, and single-use aliquot format to minimize freeze–thaw damage.
01 Titer vs total vg Total vg = titer (vg/mL) × volume (mL).
02 Is higher better? Not always; the right titer depends on dosing volume limits.
03 What specifications? Volume and aliquots can be customized to the experiment.
04 What quality matters? Integrity, empty/full ratio, purity, and activity.
Direct Answer
Titer, total vg, and specifications are not the same
Titer describes vector genomes per unit volume (vg/mL), while total vg describes the absolute number of vector genomes in a dose. The relationship is simple—total vg equals titer times volume—but the practical choice is not: high titer lets you deliver a fixed dose in a smaller volume, which matters most when the injection volume is constrained.
Research-grade AAV typically spans roughly 1012 to 1014 vg/mL, but there is no universal standard. The achievable titer depends on serotype, cassette size, GOI, and process, so the goal should be the right titer for your dose and volume, not the highest number.
The key principle: "appropriate titer" beats "highest titer." Choose by matching concentration, total vg, and quality to the experiment.
Titer
Concentration
Vector genomes per milliliter (vg/mL or GC/mL), reflecting how concentrated the preparation is.
Total vg
Absolute Dose
The total vector genomes used, calculated as titer multiplied by volume. A 1×1013 vg/mL stock at 0.1 mL gives 1×1012 vg.
Volume
Injection Constraint
For brain, spinal cord, retinal, or vitreous delivery, the volume limit often dictates the required titer.
Aliquots
Freeze–Thaw Management
Aliquoting into single-use sizes reduces repeated freeze–thaw and preserves activity.
Key Factors
What shapes the final AAV titer
Several factors determine the titer a given project can reach, which is why different AAV projects differ in achievable titer.
| Factor | How It Affects Titer | What to Consider |
|---|---|---|
| Serotype / capsid | Different capsids package and produce at different efficiencies | Serotype selection should balance tropism and production |
| Genome size | Cassettes near the ~4.7 kb limit reduce packaging and integrity | Budget ITR + promoter + GOI + regulatory + polyA |
| GOI & product | Toxic or unstable transgenes lower yield | Account for GOI size, repeats, and cell toxicity |
| Production & purification | Cell state, transfection, culture, and downstream process all affect final titer | Use a controlled, validated production workflow |
Higher titer is a real advantage only where dosing volume is limited. For volume-unconstrained experiments, the same total dose can be delivered at a lower concentration, so chasing the maximum titer is often unnecessary.
Selection
A five-step way to choose titer and specifications
Work from the experiment backward: define the dose, then the volume, then the titer and aliquots you need.
-
01
Identify the Experiment
In vitro, rodent, large animal, or microinjection.
-
02
Set the Target Dose
Define total vg per well, animal, or injection site.
-
03
Compute Volume
Divide total vg by titer to find the required volume.
-
04
Assess High Titer Need
High titer is needed only when injection volume is limited.
-
05
Plan Aliquots
Aliquot by single-use amount to avoid repeated freeze–thaw.
For in vitro work, the stock titer does not by itself determine transduction; cell type, serotype, MOI, and exposure time all matter, so a small dose-range pilot is more informative than a fixed vg/mL rule.
Quality Attributes
Titer is only one dimension of product quality
A high vg/mL product with poor integrity or a large empty-capsid fraction can underperform. Judge the product on the full quality picture.
Genome Integrity
Truncated or incomplete genomes lower the fraction of the dose that is functional.
Empty/Full Ratio
A high empty-capsid fraction adds protein without therapeutic benefit.
Purity
Residual HCP, host DNA, and impurities affect safety and dosing.
Functional Activity
Functional titer links the product to actual transduction.
Endotoxin
Endotoxin level matters for in vivo use and general safety.
Formulation Buffer
Buffer composition and stability conditions affect storage and handling.
Decision Framework
Choose by fit, not by the highest number
Each experimental context changes what matters most—titer, total vg, or quality. Matching them to the context is what makes a product choice correct.
In vitro experiments
Evaluate: cell type, serotype, MOI, and exposure time, not stock titer alone.
Decision supported: pilot a dose range rather than fix a vg/mL rule.
Rodent experiments
Evaluate: total vg, route, target tissue, and body weight together.
Decision supported: balance titer, total vg, and injection volume.
Microinjection
Evaluate: whether the target dose can fit the limited volume.
Decision supported: high titer is usually required for volume-limited delivery.
Large animal studies
Evaluate: total vg per animal and injection volume more than vg/mL alone.
Decision supported: calculate total vg first, then derive required volume.
High titer but poor quality
Evaluate: empty-capsid fraction, integrity, aggregation, and activity before relying on vg/mL.
Decision supported: vector analysis and quality confirmation.
Decision Outputs
From product choice to experiment fit
Each context is mapped to a defined selection.
Dose
Total vg per well/animal.
Concentration
Titer matched to volume.
Quality
Integrity, purity, activity.
Aliquots
Single-use freeze–thaw control.
From Question to Evidence
Creative Biolabs Support
Creative Biolabs can supply AAV matched to your titer, volume, and aliquot requirements, with the quality data to support your experiment.
02 / TITRATION
Genome titer determination
Confirm the vector genome concentration you are actually dosing. Use the measured titer to calculate a reproducible dose and select an appropriate administration volume.
03 / QUALITY
Purity and integrity
Measure empty/full ratio, integrity, and residual impurities. These quality attributes help determine whether the vector preparation is suitable for reliable downstream experiments.
04 / ACTIVITY
Functional activity
Verify the product transduces and expresses in a relevant system. Functional testing confirms that the measured vector quantity translates into the expected biological activity.
05 / ANALYSIS
Integrated vector analysis
Combine titer, identity, integrity, and purity for a complete product picture. An integrated data package supports batch comparison and more confident material selection.
Selected Reading
Scientific context
Review
Buck TM and Wijnholds J. Recombinant Adeno-Associated Viral Vectors (rAAV)—Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. International Journal of Molecular Sciences. 2020;21(12):4197. View article.
Cost Analysis
Gálvez-Montes C, et al. rAAV production cost analysis: indication-specific cost per dose and reduction strategies. Gene Therapy. 2026. View article.
Regulatory Guideline
European Medicines Agency. Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors. View guideline.
FAQ
AAV titer and specification questions
Choose the right AAV titer and specifications for your experiment
Share your serotype, cassette, target tissue, dosing plan, and volume limits. We can help you select the right titer, volume, and aliquots.
Tell us about your AAV product need and the decision the material must support. Our scientific team will follow up with a project-specific recommendation.
Inquiry NowFor research use only. Not intended for any clinical use.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
